CYP2C19 genotype and the PPIs – focus on rabeprazole |
| |
| Authors: | P. W. Y LIM K. L. GOH B. C. Y. WONG |
| |
| Affiliation: | Eisai Co., Ltd, c/o Eisai Asia Regional Services Pte Ltd, Singapore,;University of Malaya, Kuala Lumpur, Malaysia,;Department of Medicine, University of Hong Kong, Hong Kong |
| |
| Abstract: | Abstract: Amongst all the proton pump inhibitors (PPI), the hepatic metabolism of rabeprazole is least dependent on the CYP4502C19 system. Rabeprazole is therefore the PPI least affected by CYP4502C19 genetic polymorphism. This unique feature of rabeprazole complements rabeprazole's fast onset of action, and may lead to profound and consistent inhibition of gastric acid secretion in the treatment of acid-related disorders. |
| |
| Keywords: | acid-related disorders consistent inhibition CYP4502C19 genetic polymorphism rabeprazole |
|
|
